Semax is a synthetic peptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10), with the addition of a Pro-Gly-Pro tripeptide sequence to enhance stability and bioavailability. Originally developed in Russia, Semax has been extensively studied for its potential nootropic and neuroprotective properties.
Research suggests Semax may influence the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), both critical for neuronal health and plasticity. Studies have explored its effects on cognitive function, memory formation, and attention in various experimental models.
Semax demonstrates a favorable safety profile in research settings and has been investigated for applications in cerebrovascular conditions, cognitive enhancement, and stress-related research paradigms.
Researchers should refer to peer-reviewed publications for primary sources on this compound. Semax is sold strictly for laboratory research use and is not intended for human or veterinary use.